Compile Data Set for Download or QSAR
Found 123 with Last Name = 'bodary' and Initial = 's'
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101766((S)-2-Ethenesulfonylamino-3-({5-[2-(1,4,5,6-tetrah...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101773((S)-2-(Naphthalene-1-sulfonylamino)-3-({5-[2-(1,4,...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101755((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101763((S)-2-(3-Chloro-propane-1-sulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101779((S)-2-(Quinoline-8-sulfonylamino)-3-({5-[2-(1,4,5,...)copy SMILEScopy InChI
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)copy SMILEScopy InChI
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101771((S)-2-(Propane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-...)copy SMILEScopy InChI
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101772((S)-2-Chloromethanesulfonylamino-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101764((S)-2-(Butane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-t...)copy SMILEScopy InChI
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101751((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 5nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101754((S)-2-Methanesulfonylamino-3-({5-[2-(1,4,5,6-tetra...)copy SMILEScopy InChI
Affinity DataIC50: 5nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 6nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101765((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)copy SMILEScopy InChI
Affinity DataIC50: 7nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 7nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101767(3-Benzo[1,3]dioxol-5-yl-3-{[5-((E)-3-guanidino-3-o...)copy SMILEScopy InChI
Affinity DataIC50: 8nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 9nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50403867(CHEMBL2115098)copy SMILEScopy InChI
Affinity DataIC50: 9nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101760((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101752(3-Benzo[1,3]dioxol-5-yl-3-{[5-(3-guanidino-3-oxo-p...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 11nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)copy SMILEScopy InChI
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)copy SMILEScopy InChI
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101773((S)-2-(Naphthalene-1-sulfonylamino)-3-({5-[2-(1,4,...)copy SMILEScopy InChI
Affinity DataIC50: 13nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101758(3-Benzo[1,3]dioxol-5-yl-3-{[5-(2-guanidinocarbonyl...)copy SMILEScopy InChI
Affinity DataIC50: 16nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 17nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101763((S)-2-(3-Chloro-propane-1-sulfonylamino)-3-({5-[2-...)copy SMILEScopy InChI
Affinity DataIC50: 17nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50085011(2-Benzyloxycarbonylamino-3-(2-{(S)-4-[3-(4,5-dihyd...)copy SMILEScopy InChI
Affinity DataIC50: 20nMAssay Description:Inhibition of Kistrin binding to integrin alphaV-beta3More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q290249VPubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101771((S)-2-(Propane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-...)copy SMILEScopy InChI
Affinity DataIC50: 22nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101755((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)copy SMILEScopy InChI
Affinity DataIC50: 26nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)copy SMILEScopy InChI
Affinity DataIC50: 26nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101776(3-Benzo[1,3]dioxol-5-yl-3-({5-[(E)-2-(1,4,5,6-tetr...)copy SMILEScopy InChI
Affinity DataIC50: 32nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101780(3-Benzo[1,3]dioxol-5-yl-3-({5-[2-(1,4,5,6-tetrahyd...)copy SMILEScopy InChI
Affinity DataIC50: 33nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)copy SMILEScopy InChI
Affinity DataIC50: 35nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101775(3-{[5-(3-Guanidino-3-oxo-propyl)-thiophene-2-carbo...)copy SMILEScopy InChI
Affinity DataIC50: 35nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101777((2S)-2-{[(benzyloxy)carbonyl]amino}-3-({5-[2-(carb...)copy SMILEScopy InChI
Affinity DataIC50: 39nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50085018(3-(2-{(S)-4-[3-(1H-Benzoimidazol-2-ylamino)-propyl...)copy SMILEScopy InChI
Affinity DataIC50: 40nMAssay Description:Inhibition of Kistrin binding to integrin alphaV-beta3More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q290249VPubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101766((S)-2-Ethenesulfonylamino-3-({5-[2-(1,4,5,6-tetrah...)copy SMILEScopy InChI
Affinity DataIC50: 40nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101762((S)-2-Benzyloxycarbonylamino-3-{[5-(2-guanidinocar...)copy SMILEScopy InChI
Affinity DataIC50: 41nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101779((S)-2-(Quinoline-8-sulfonylamino)-3-({5-[2-(1,4,5,...)copy SMILEScopy InChI
Affinity DataIC50: 47nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)copy SMILEScopy InChI
Affinity DataIC50: 55nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101762((S)-2-Benzyloxycarbonylamino-3-{[5-(2-guanidinocar...)copy SMILEScopy InChI
Affinity DataIC50: 60nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101765((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)copy SMILEScopy InChI
Affinity DataIC50: 63nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)copy SMILEScopy InChI
Affinity DataIC50: 65nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Aventis Pharma Deutschland GmbH

Curated by ChEMBL
LigandPNGBDBM50101774(3-Biphenyl-4-yl-3-{[5-(3-guanidino-3-oxo-propyl)-t...)copy SMILEScopy InChI
Affinity DataIC50: 69nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2N87930PubMed
Displayed 1 to 50 (of 123 total ) | Next | Last >>
Jump to: